147 related articles for article (PubMed ID: 38862591)
1. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
Prasanth MI; Wannigama DL; Reiersen AM; Thitilertdecha P; Prasansuklab A; Tencomnao T; Brimson S; Brimson JM
Sci Rep; 2024 Jun; 14(1):13462. PubMed ID: 38862591
[TBL] [Abstract][Full Text] [Related]
2. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Facente SN; Reiersen AM; Lenze EJ; Boulware DR; Klausner JD
Drugs; 2021 Dec; 81(18):2081-2089. PubMed ID: 34851510
[TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine for the treatment of COVID-19.
Nyirenda JL; Sofroniou M; Toews I; Mikolajewska A; Lehane C; Monsef I; Abu-Taha A; Maun A; Stegemann M; Schmucker C
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015391. PubMed ID: 36103313
[TBL] [Abstract][Full Text] [Related]
4. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Reis G; Dos Santos Moreira-Silva EA; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; de Souza Campos VH; Nogueira AMR; de Almeida APFG; Callegari ED; de Figueiredo Neto AD; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Glushchenko AV; Rayner CR; Lenze EJ; Reiersen AM; Guyatt GH; Mills EJ;
Lancet Glob Health; 2022 Jan; 10(1):e42-e51. PubMed ID: 34717820
[TBL] [Abstract][Full Text] [Related]
5. The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.
Nakhaee H; Zangiabadian M; Bayati R; Rahmanian M; Ghaffari Jolfayi A; Rakhshanderou S
PLoS One; 2022; 17(10):e0267423. PubMed ID: 36201406
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
Lenze EJ; Mattar C; Zorumski CF; Stevens A; Schweiger J; Nicol GE; Miller JP; Yang L; Yingling M; Avidan MS; Reiersen AM
JAMA; 2020 Dec; 324(22):2292-2300. PubMed ID: 33180097
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials.
Zhou Q; Zhao G; Pan Y; Zhang Y; Ni Y
PLoS One; 2024; 19(5):e0300512. PubMed ID: 38753761
[TBL] [Abstract][Full Text] [Related]
9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants-A Scoping Review.
Bonnet U; Juckel G
J Clin Psychopharmacol; 2022 May-Jun 01; 42(3):284-292. PubMed ID: 35420565
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Deng J; Rayner D; Ramaraju HB; Abbas U; Garcia C; Heybati K; Zhou F; Huang E; Park YJ; Moskalyk M
Clin Microbiol Infect; 2023 May; 29(5):578-586. PubMed ID: 36657488
[TBL] [Abstract][Full Text] [Related]
13. Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.
Bhuta S; Khokher W; Kesireddy N; Iftikhar S; Beran A; Mhanna M; Patel NJ; Patel M; Burmeister C; Assaly R
Am J Ther; 2022 May-Jun 01; 29(3):e298-e304. PubMed ID: 35383578
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials.
Vatvani AD; Kurniawan A; Hariyanto TI
Ann Pharmacother; 2023 Dec; 57(12):1389-1397. PubMed ID: 37002592
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use.
Foletto VS; da Rosa TF; Serafin MB; Hörner R
Eur J Clin Pharmacol; 2022 Oct; 78(10):1601-1611. PubMed ID: 35943535
[TBL] [Abstract][Full Text] [Related]
17. Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Stewart TG; Rebolledo PA; Mourad A; Lindsell CJ; Boulware DR; McCarthy MW; Thicklin F; Garcia Del Sol IT; Bramante CT; Lenert LA; Lim S; Williamson JC; Cardona OQ; Scott J; Schwasinger-Schmidt T; Ginde AA; Castro M; Jayaweera D; Sulkowski M; Gentile N; McTigue K; Felker GM; DeLong A; Wilder R; Rothman RL; Collins S; Dunsmore SE; Adam SJ; Hanna GJ; Shenkman E; Hernandez AF; Naggie S;
JAMA; 2023 Dec; 330(24):2354-2363. PubMed ID: 37976072
[TBL] [Abstract][Full Text] [Related]
18. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Bramante CT; Huling JD; Tignanelli CJ; Buse JB; Liebovitz DM; Nicklas JM; Cohen K; Puskarich MA; Belani HK; Proper JL; Siegel LK; Klatt NR; Odde DJ; Luke DG; Anderson B; Karger AB; Ingraham NE; Hartman KM; Rao V; Hagen AA; Patel B; Fenno SL; Avula N; Reddy NV; Erickson SM; Lindberg S; Fricton R; Lee S; Zaman A; Saveraid HG; Tordsen WJ; Pullen MF; Biros M; Sherwood NE; Thompson JL; Boulware DR; Murray TA;
N Engl J Med; 2022 Aug; 387(7):599-610. PubMed ID: 36070710
[TBL] [Abstract][Full Text] [Related]
19. The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial).
Siripongboonsitti T; Tawinprai K; Payoong P; Mahanonda N
J Infect Public Health; 2023 Dec; 16(12):2010-2016. PubMed ID: 37890224
[TBL] [Abstract][Full Text] [Related]
20. Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.
Mahdi M; Hermán L; Réthelyi JM; Bálint BL
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
